The Problem:


Current State of ALS Research

  • Little concentrated effort  by Pharma and Biotech companies  to produce a drug 
  • Little is known about the disease.  
    • No biomarkers. 
    • Hard to create a cure for something that can’t be identified
  • No new ALS drug in over 22 years since Relizolein 1995
    • Only ALS drug available (upside is 10% reduction in decay rate)
    • Radicava, in 2017 was a repurposed stroke drug;  Questionable success


Rare disease = low revenue potential

  • $$$$   US Cancer population = 2 milion

  • $  US ALS Population = 20,000 to 25,000


Today's ALS Scenario

The symptoms

Person exhibits symptoms involving “muscle fatigue” and fasciculations on some part of their body extremities or tongue 

The diagnosis

Spends 4-6 months testing for AIDS, MS, Lime Disease, heavy metals, etc.

Usually at least two nerve tests

When the person has none of the above they are diagnosed as having ALS

The treatment

Given Relizole, counseled about Radicava and told of clinical trials (most of which they will be ineligible for) 

Begin the dying and accommodation process 

(14 months to 10 years +)

Wheelchairs, splints/braces, home accommodations, breathing machines,   ventilators, feeding tubes, IV Ports, Hospice